Do HTA organisations consider manufacturers’ costs in relation to drug price? https://t.co/UyqAkwqkpn Despite the attention given to manufacturers’ costs in relation to price in public debates, it does not seem to get consideration in the reimbursement rep
RT @werner_brouwer: New OA paper of Joost Enzing, @BeateSander et al: Do Health Technology Assessment organisations consider manufacturers’…
New OA paper of Joost Enzing, @BeateSander et al: Do Health Technology Assessment organisations consider manufacturers’ costs in relation to drug price? Based on reimbursement reports the answer is: not systematically and explicitly. Time to change?